Q32 Bio/$QTTB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Q32 Bio
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
- Ticker
- $QTTB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 22
- Headquarters
- Waltham, United States
- Website
- www.q32bio.com
Q32 Bio Metrics
BasicAdvanced
$459m
6.78
$2.27
-0.33
-
Price and volume
Market cap
$459m
Beta
-0.33
52-week high
$23.57
52-week low
$1.62
Average daily volume
1.9m
Financial strength
Current ratio
19.796
Quick ratio
19.676
Long term debt to equity
4.307
Total debt to equity
4.307
Interest coverage (TTM)
14.31%
Profitability
EBITDA (TTM)
21.818
Gross margin (TTM)
73.30%
Net profit margin (TTM)
62.87%
Operating margin (TTM)
39.94%
Revenue per employee (TTM)
$2,440,000
Management effectiveness
Return on assets (TTM)
14.74%
Return on equity (TTM)
72.14%
Valuation
Price to earnings (TTM)
6.777
Price to revenue (TTM)
4.254
Price to book
3.45
Price to tangible book (TTM)
3.45
Price to free cash flow (TTM)
-11.529
Free cash flow yield (TTM)
-8.67%
Free cash flow per share (TTM)
-1.337
Growth
Earnings per share change (TTM)
-152.91%
What the Analysts think about Q32 Bio
Majority rating from 3 analysts.
| Month | Buy | Hold | Sell | Analysts | Majority rating |
|---|---|---|---|---|---|
| December 2023 | 0 | 1 | 0 | 1 | Hold |
| January 2024 | 0 | 1 | 0 | 1 | Hold |
| February 2024 | 0 | 1 | 0 | 1 | Hold |
| April 2024 | 2 | 0 | 0 | 2 | Buy |
| May 2024 | 3 | 0 | 0 | 3 | Buy |
| June 2024 | 3 | 0 | 0 | 3 | Buy |
Q32 Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.